Venous thromboembolism (VTE), deep vein thrombosis (DVT), pulmonary embolism (PE)

Indication for Dalteparin

Population group: Suitable for both men and women, only adults (18 years old or older)

Treatment of venous thromboembolism (VTE) presenting clinically as deep vein thrombosis (DVT), pulmonary embolism (PE) or both.

For this indication, competent medicine agencies globally authorize below treatments:

200 IU/kg in 2 divided doses daily

Route of admnistration

Subcutaneous

Defined daily dose

200 - 200 [iU] per kg of body weight

Dosage regimen

From 100 To 100 [iU] per kg of body weight 2 time(s) per day every day

Detailed description

Twice daily administration

A dose of 100 IU/kg body weight administered s.c twice daily can be used for patients with increased risk of bleeding. Monitoring of the treatment is generally not necessary but can be performed with a functional anti-Factor Xa assay. Maximum plasma levels are obtained 3-4 hours after s.c injection, when samples should be taken. Recommended plasma levels are between 0.5-1.0 IU (anti-Factor Xa)/ml.

Simultaneous anticoagulation with oral vitamin K antagonists can be started immediately. Treatment with Fragmin is continued until the prothrombin complex levels (factor II, VII, IX and X) have decreased to a therapeutic level. At least five days of combined treatment is normally required.

200 IU/kg once daily

Route of admnistration

Subcutaneous

Defined daily dose

200 - 200 [iU] per kg of body weight

Dosage regimen

From 200 To 200 [iU] per kg of body weight once every day

Detailed description

Once daily administration

200 IU/kg body weight is administered s.c once daily. Monitoring of the anticoagulant effect is not necessary. The single daily dose should not exceed 18,000 IU.

Simultaneous anticoagulation with oral vitamin K antagonists can be started immediately. Treatment with dalteparin is continued until the prothrombin complex levels (factor II, VII, IX and X) have decreased to a therapeutic level. At least five days of combined treatment is normally required.

Active ingredient

Dalteparin is an antithrombotic agent, which acts mainly through its ability to potentiate the inhibition of Factor Xa and thrombin by antithrombin. It has a relatively higher ability to potentiate Factor Xa inhibition than to prolong plasma clotting time (APTT).

Read more about Dalteparin

Related medicines

Develop a tailored medication plan for your case, considering factors such as age, gender, and health history

Ask the Reasoner